Deputy, I never said the company currently has the market cornered for blood-based AD diagnostic testing. That only happens when all 3 testing modalities are brought to market. LymPro still has to achieve CLIA certification and FDA approval, as well as approval in the EU. The two tests to be licensed will have to undergo further testing before commercialization.

It is asinine to think the company has cornered the market when 2 of the 3 tests haven't even reached the market. GC was referring to some point in the future, not the current state of things. Think before you post.